009420 — Hanall Biopharma Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual cashflow statement for Hanall Biopharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	8,896	251	3,509	-1,805	-5,559
Depreciation
Amortisation
Non-Cash Items	4,929	6,425	2,877	4,870	8,734
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-15,710	15,475	20,010	3,174	-9,076
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	840	25,204	29,643	9,360	-2,340
Capital Expenditures	-9,002	-7,677	-9,198	-23,068	-14,116
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	17,032	-2,915	-2,690	-4,425	-4,716
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	8,030	-10,592	-11,887	-27,493	-18,832
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-307	-10,644	-814	760	29,566
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	8,594	4,047	16,882	-17,336	8,357